Calithera Biosciences Stock Cash Flow From Operations
| CALADelisted Stock | USD 0.05 0.00 0.00% |
Calithera Biosciences fundamentals help investors to digest information that contributes to Calithera Biosciences' financial success or failures. It also enables traders to predict the movement of Calithera Pink Sheet. The fundamental analysis module provides a way to measure Calithera Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Calithera Biosciences pink sheet.
Calithera |
Calithera Biosciences Company Cash Flow From Operations Analysis
Calithera Biosciences' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Calithera Biosciences Cash Flow From Operations | (43.61 M) |
Most of Calithera Biosciences' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Calithera Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Calithera Biosciences has (43.61 Million) in Cash Flow From Operations. This is 108.27% lower than that of the Biotechnology sector and 169.75% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 104.49% higher than that of the company.
Calithera Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calithera Biosciences' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Calithera Biosciences could also be used in its relative valuation, which is a method of valuing Calithera Biosciences by comparing valuation metrics of similar companies.Calithera Biosciences is currently under evaluation in cash flow from operations category among its peers.
Calithera Fundamentals
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | (1.1 M) | ||||
| Shares Outstanding | 4.87 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 26.76 % | ||||
| Number Of Shares Shorted | 417.28 K | ||||
| Price To Earning | (14.08) X | ||||
| Price To Book | 1.86 X | ||||
| Price To Sales | 1.71 X | ||||
| Gross Profit | (42.7 M) | ||||
| EBITDA | (43.77 M) | ||||
| Net Income | (39.65 M) | ||||
| Cash And Equivalents | 41.79 M | ||||
| Cash Per Share | 8.59 X | ||||
| Total Debt | 1.67 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 4.82 X | ||||
| Book Value Per Share | (0.40) X | ||||
| Cash Flow From Operations | (43.61 M) | ||||
| Short Ratio | 0.78 X | ||||
| Earnings Per Share | (1.59) X | ||||
| Price To Earnings To Growth | (0.29) X | ||||
| Target Price | 5.0 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 341.07 K | ||||
| Total Asset | 28.68 M | ||||
| Retained Earnings | (512.62 M) | ||||
| Working Capital | 19.23 M | ||||
| Current Asset | 72.5 M | ||||
| Current Liabilities | 3.83 M | ||||
| Z Score | -29.14 | ||||
| Net Asset | 28.68 M |
About Calithera Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calithera Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calithera Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calithera Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Calithera Pink Sheet
If you are still planning to invest in Calithera Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calithera Biosciences' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |